24
Incidence of New Onset All Grade Non-hematologic Adverse Events Regardless of Causality 24 Incidence (%) Ruxolitinib 0–<12 months (n=155) 12–<24 months (n=130) 24–<36 months (n=103) 36 months (n=82) Fatigue Diarrhea Ecchymosis Peripheral edema Dyspnea Dizziness Pain in extremity Headache Nausea Constipation Abdominal pain Insomnia Vomiting Pyrexia Cough Arthralgia Upper respiratory tract infection There was no change in the rate, distribution, or severity of nonhematologic adverse events in the ruxolitinib group with longer-term treatment; most nonhematologic adverse events were grade 1 or 2 Percentage of patients for each event was based on the effective sample size of the time interval (number of patients at risk at the beginning of the interval minus half of the censored patients during the time interval). Adverse event is included if the incidence was >10% at any yearly interval. ASH 2013